English

INNOVATE BIOPHARMACEUTICALS, INC.

EDGAR

INNT Quarterly report (10-Q) · filed 2023-05-15

49 filing records in this dataset, filed from 2015-11-10 to 2023-05-15. Reported financial figures are available; chart coverage varies by period.

Inspect reported changes Compare with another company Historical disclosures Search filings Segments

Watchlist

Cash and cash equivalents: 6.9 million USD 2023-03-31 Source
Exact value

6900000 USD
Long-term debt including current maturities: Not available
Shares outstanding: 14.3 million shares 2023-03-31 Source
Exact value

14336356 shares

Reported share-count change

-94.45% · -244 million shares

Year-over-year change in reported shares. Splits, issuance and buybacks can affect this figure; it does not isolate employee compensation or economic dilution.

Exact inputs and evidence

258235418 shares · 2022-03-31· Source
14336356 shares · 2023-03-31· Source

Trailing twelve months

The four most recent complete quarters added together. This gives a full-year view that includes the latest quarterly results.

Net income

-46.3 million USD

2022-04-01 – 2023-03-31

Exact inputs and evidence

Net income: -11130102 USD · 2022-04-01 – 2022-06-30 Source
Net income: -9354671 USD · 2022-07-01 – 2022-09-30 Source
Net income: -43766415 USD · 2022-01-01 – 2022-12-31 Source
Net income: -31836512 USD · 2022-01-01 – 2022-09-30 Source
Net income: -13868457 USD · 2023-01-01 – 2023-03-31 Source

Operating cash flow

-37.2 million USD

2022-04-01 – 2023-03-31

Exact inputs and evidence

Operating cash flow: -17534655 USD · 2022-01-01 – 2022-06-30 Source
Operating cash flow: -9748331 USD · 2022-01-01 – 2022-03-31 Source
Operating cash flow: -27504607 USD · 2022-01-01 – 2022-09-30 Source
Operating cash flow: -17534655 USD · 2022-01-01 – 2022-06-30 Source
Operating cash flow: -37243217 USD · 2022-01-01 – 2022-12-31 Source
Operating cash flow: -27504607 USD · 2022-01-01 – 2022-09-30 Source
Operating cash flow: -9749676 USD · 2023-01-01 – 2023-03-31 Source

Capital expenditure

0 USD

2022-04-01 – 2023-03-31

Exact inputs and evidence

Capital expenditure: 2842 USD · 2022-01-01 – 2022-06-30 Source
Capital expenditure: 2842 USD · 2022-01-01 – 2022-03-31 Source
Capital expenditure: 2842 USD · 2022-01-01 – 2022-09-30 Source
Capital expenditure: 2842 USD · 2022-01-01 – 2022-06-30 Source
Capital expenditure: 2842 USD · 2022-01-01 – 2022-12-31 Source
Capital expenditure: 2842 USD · 2022-01-01 – 2022-09-30 Source
Capital expenditure: 0 USD · 2023-01-01 – 2023-03-31 Source

Free cash flow

-37.2 million USD

2022-04-01 – 2023-03-31

Exact inputs and evidence

Operating cash flow: -17534655 USD · 2022-01-01 – 2022-06-30 Source
Operating cash flow: -9748331 USD · 2022-01-01 – 2022-03-31 Source
Operating cash flow: -27504607 USD · 2022-01-01 – 2022-09-30 Source
Operating cash flow: -17534655 USD · 2022-01-01 – 2022-06-30 Source
Operating cash flow: -37243217 USD · 2022-01-01 – 2022-12-31 Source
Operating cash flow: -27504607 USD · 2022-01-01 – 2022-09-30 Source
Operating cash flow: -9749676 USD · 2023-01-01 – 2023-03-31 Source
Capital expenditure: 2842 USD · 2022-01-01 – 2022-06-30 Source
Capital expenditure: 2842 USD · 2022-01-01 – 2022-03-31 Source
Capital expenditure: 2842 USD · 2022-01-01 – 2022-09-30 Source
Capital expenditure: 2842 USD · 2022-01-01 – 2022-06-30 Source
Capital expenditure: 2842 USD · 2022-01-01 – 2022-12-31 Source
Capital expenditure: 2842 USD · 2022-01-01 – 2022-09-30 Source
Capital expenditure: 0 USD · 2023-01-01 – 2023-03-31 Source

Includes later revisions to earlier periods. Annual charts exclude incomplete years.

Latest filing recorded: 2023-05-15.

Financial data available through: 2022-12-31.

Coverage by financial measure

revenue: No compatible figures in this window
Operating income: 9 of 11 periods available· newest 2022-12-31
Net income: 9 of 11 periods available· newest 2022-12-31
Operating cash flow: 9 of 11 periods available· newest 2022-12-31
Capital expenditure: 6 of 11 periods available· newest 2022-12-31
Total assets: 9 of 11 periods available· newest 2022-12-31
Total liabilities: 5 of 11 periods available· newest 2022-12-31
Current assets: 9 of 11 periods available· newest 2022-12-31
Current liabilities: 9 of 11 periods available· newest 2022-12-31
Cash and cash equivalents: 7 of 11 periods available· newest 2022-12-31
long term debt: No compatible figures in this window
Shares outstanding: 9 of 11 periods available· newest 2022-12-31

Coverage describes values retained in this snapshot. Missing values are not zero; loading limits are reported separately.

What changed year over year

Latest complete year compared with the corresponding period one year earlier. These are measured changes; they do not establish their business causes.

Net income
−USD 6.99 million

Prior period

−USD 36.78 million

2021-01-01 – 2021-12-31
Current period

−USD 43.77 million

2022-01-01 – 2022-12-31

Exact inputs and evidence

-43766415 − -36779400 = -6987015 USD

-36779400 USD · 2021-01-01 – 2021-12-31
Inspect prior input Prior source
-43766415 USD · 2022-01-01 – 2022-12-31
Inspect current input Current source

Share or cite

Citation for Year-over-year change in Net income · INNOVATE BIOPHARMACEUTICALS, INC. · 2022-12-31 INNOVATE BIOPHARMACEUTICALS, INC. (edgar:1551986) Year-over-year change in Net income: -6987015 USD Concept: fundies:NetIncome Period: 2022-01-01 to 2022-12-31 Values: Latest reported Published: 2026-11-02T18:37:57Z Snapshot: df701299cb5fffd82f916455b60e1c4efcc69a41535e456c8ef8cf69576cef32 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1551986?view=overview&cadence=annual&surface=latest#period-changes-title Computed: Current period minus corresponding prior-year period Input fundies:NetIncome: -43766415 USD (2022-01-01 to 2022-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1551986/000155198623000021/nmtr-20221231.htm#1037802 Filing: 000155198623000021 Input fundies:NetIncome: -36779400 USD (2021-01-01 to 2021-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1551986/000155198623000021/nmtr-20221231.htm#1038643 Filing: 000155198623000021
The citation records this snapshot. The page link may show a newer release later.
Operating cash flow
−USD 7.76 million

Prior period

−USD 29.48 million

2021-01-01 – 2021-12-31
Current period

−USD 37.24 million

2022-01-01 – 2022-12-31

Exact inputs and evidence

-37243217 − -29478275 = -7764942 USD

-29478275 USD · 2021-01-01 – 2021-12-31
Inspect prior input Prior source
-37243217 USD · 2022-01-01 – 2022-12-31
Inspect current input Current source

Share or cite

Citation for Year-over-year change in Operating cash flow · INNOVATE BIOPHARMACEUTICALS, INC. · 2022-12-31 INNOVATE BIOPHARMACEUTICALS, INC. (edgar:1551986) Year-over-year change in Operating cash flow: -7764942 USD Concept: fundies:OperatingCashFlow Period: 2022-01-01 to 2022-12-31 Values: Latest reported Published: 2026-11-02T18:37:57Z Snapshot: df701299cb5fffd82f916455b60e1c4efcc69a41535e456c8ef8cf69576cef32 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1551986?view=overview&cadence=annual&surface=latest#period-changes-title Computed: Current period minus corresponding prior-year period Input fundies:OperatingCashFlow: -37243217 USD (2022-01-01 to 2022-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1551986/000155198623000021/nmtr-20221231.htm#1059432 Filing: 000155198623000021 Input fundies:OperatingCashFlow: -29478275 USD (2021-01-01 to 2021-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1551986/000155198623000021/nmtr-20221231.htm#1060154 Filing: 000155198623000021
The citation records this snapshot. The page link may show a newer release later.
Capital expenditure
-77.2%

Prior period

USD 12,476

2021-01-01 – 2021-12-31
Current period

USD 2,842

2022-01-01 – 2022-12-31

Exact inputs and evidence

2842 − 12476 = -9634 USD

12476 USD · 2021-01-01 – 2021-12-31
Inspect prior input Prior source
2842 USD · 2022-01-01 – 2022-12-31
Inspect current input Current source

Share or cite

Citation for Year-over-year change in Capital expenditure · INNOVATE BIOPHARMACEUTICALS, INC. · 2022-12-31 INNOVATE BIOPHARMACEUTICALS, INC. (edgar:1551986) Year-over-year change in Capital expenditure: -9634 USD Concept: fundies:CapitalExpenditure Period: 2022-01-01 to 2022-12-31 Values: Latest reported Published: 2026-11-02T18:37:57Z Snapshot: df701299cb5fffd82f916455b60e1c4efcc69a41535e456c8ef8cf69576cef32 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1551986?view=overview&cadence=annual&surface=latest#period-changes-title Computed: Current period minus corresponding prior-year period Input fundies:CapitalExpenditure: 2842 USD (2022-01-01 to 2022-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1551986/000155198623000021/nmtr-20221231.htm#1061946 Filing: 000155198623000021 Input fundies:CapitalExpenditure: 12476 USD (2021-01-01 to 2021-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1551986/000155198623000021/nmtr-20221231.htm#1062596 Filing: 000155198623000021
The citation records this snapshot. The page link may show a newer release later.

Comparable inputs unavailable for: Revenue.

Where revenue goes

How a period’s revenue divides into costs and what remains as profit. Items marked Derived are calculated by subtraction from reported figures.

Revenue is not reported for this company, so its costs cannot be shown as a share of it.

Growth

Sales over time and how quickly they are changing.

Revenue

Revenue reported for each complete financial period.

Not enough comparable data to show this history.

Values and sources

Revenue values and source evidence
Period	Series	Value	Source evidence

Revenue growth

Change in revenue from the same financial period one year earlier.

Not enough comparable data to show this history.

Values and sources

Revenue growth values and source evidence
Period	Series	Value	Source evidence

Profit and cash

How much revenue becomes profit, and how much cash operations generate.

Profit margins

Operating income, net income and free cash flow as a share of revenue.

Not enough comparable data to show this history.

Operating margin
Net margin
Free cash flow margin

Values and sources

Profit margins values and source evidence
Period	Series	Value	Source evidence

Operating cash flow

Cash generated by the company’s normal business operations.

Not enough comparable data to show this history.

Values and sources

Operating cash flow values and source evidence
Period	Series	Value	Source evidence

Free cash flow

Operating cash flow minus capital expenditure for the same period and unit.

Not enough comparable data to show this history.

Values and sources

Free cash flow values and source evidence
Period	Series	Value(USD)	Source evidence

Balance sheet

Liabilities and short-term ability to meet obligations at each period end.

Liabilities to assets

Total liabilities as a share of total assets.

Not enough comparable data to show this history.

Values and sources

Liabilities to assets values and source evidence
Period	Series	Value	Source evidence

Current assets to current liabilities

Current assets divided by current liabilities.

Not enough comparable data to show this history.

Values and sources

Current assets to current liabilities values and source evidence
Period	Series	Value	Source evidence

Cash generation

Compare reported profit with operating cash and capital spending. Free cash flow is calculated as operating cash flow minus capital expenditure when both exact, consolidated amounts match the same period and unit.

Cash generation by annual reporting period
Period	Net income	Operating cash flow	Capital expenditure	Free cash flow
2014 2014-01-01 – 2014-12-31	−USD 11.06 million Exact value Exact value: -11057000 USD 2014-01-01 – 2014-12-31: -11057000 USD Inspect Net Income Open source Share or cite Citation for Net Income · INNOVATE BIOPHARMACEUTICALS, INC. · 2014-12-31 INNOVATE BIOPHARMACEUTICALS, INC. (edgar:1551986) Net Income: -11057000 USD Concept: fundies:NetIncome Period: 2014-01-01 to 2014-12-31 Values: Latest reported Published: 2026-11-02T18:37:57Z Snapshot: df701299cb5fffd82f916455b60e1c4efcc69a41535e456c8ef8cf69576cef32 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1551986/explain?concept=fundies%3ANetIncome&period=2014-12-31&surface=latest&period_type=duration&start=2014-01-01&unit=USD&dimensions= Input fundies:NetIncome: -11057000 USD (2014-01-01 to 2014-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1551986/000114420417007977/msdi-20160930.xml#640162 Filing: 000114420417007977 The citation records this snapshot. The page link may show a newer release later.	−USD 7.45 million Exact value Exact value: -7452000 USD 2014-01-01 – 2014-12-31: -7452000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · INNOVATE BIOPHARMACEUTICALS, INC. · 2014-12-31 INNOVATE BIOPHARMACEUTICALS, INC. (edgar:1551986) Operating Cash Flow: -7452000 USD Concept: fundies:OperatingCashFlow Period: 2014-01-01 to 2014-12-31 Values: Latest reported Published: 2026-11-02T18:37:57Z Snapshot: df701299cb5fffd82f916455b60e1c4efcc69a41535e456c8ef8cf69576cef32 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1551986/explain?concept=fundies%3AOperatingCashFlow&period=2014-12-31&surface=latest&period_type=duration&start=2014-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -7452000 USD (2014-01-01 to 2014-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1551986/000114420417007977/msdi-20160930.xml#645964 Filing: 000114420417007977 The citation records this snapshot. The page link may show a newer release later.	Unavailable Not reported for this period.	Unavailable Free cash flow cannot be calculated because Capital expenditure is unavailable for this period.
2015 2015-01-01 – 2015-12-31	−USD 8.74 million Exact value Exact value: -8741000 USD 2015-01-01 – 2015-12-31: -8741000 USD Inspect Net Income Open source Share or cite Citation for Net Income · INNOVATE BIOPHARMACEUTICALS, INC. · 2015-12-31 INNOVATE BIOPHARMACEUTICALS, INC. (edgar:1551986) Net Income: -8741000 USD Concept: fundies:NetIncome Period: 2015-01-01 to 2015-12-31 Values: Latest reported Published: 2026-11-02T18:37:57Z Snapshot: df701299cb5fffd82f916455b60e1c4efcc69a41535e456c8ef8cf69576cef32 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1551986/explain?concept=fundies%3ANetIncome&period=2015-12-31&surface=latest&period_type=duration&start=2015-01-01&unit=USD&dimensions= Input fundies:NetIncome: -8741000 USD (2015-01-01 to 2015-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1551986/000114420417017815/msdi-20161231.xml#106772 Filing: 000114420417017815 The citation records this snapshot. The page link may show a newer release later.	−USD 1.73 million Exact value Exact value: -1730000 USD 2015-01-01 – 2015-12-31: -1730000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · INNOVATE BIOPHARMACEUTICALS, INC. · 2015-12-31 INNOVATE BIOPHARMACEUTICALS, INC. (edgar:1551986) Operating Cash Flow: -1730000 USD Concept: fundies:OperatingCashFlow Period: 2015-01-01 to 2015-12-31 Values: Latest reported Published: 2026-11-02T18:37:57Z Snapshot: df701299cb5fffd82f916455b60e1c4efcc69a41535e456c8ef8cf69576cef32 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1551986/explain?concept=fundies%3AOperatingCashFlow&period=2015-12-31&surface=latest&period_type=duration&start=2015-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -1730000 USD (2015-01-01 to 2015-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1551986/000114420417017815/msdi-20161231.xml#128240 Filing: 000114420417017815 The citation records this snapshot. The page link may show a newer release later.	Unavailable Not reported for this period.	Unavailable Free cash flow cannot be calculated because Capital expenditure is unavailable for this period.
2016 2016-01-01 – 2016-12-31	−USD 6.21 million Exact value Exact value: -6213000 USD 2016-01-01 – 2016-12-31: -6213000 USD Inspect Net Income Open source Share or cite Citation for Net Income · INNOVATE BIOPHARMACEUTICALS, INC. · 2016-12-31 INNOVATE BIOPHARMACEUTICALS, INC. (edgar:1551986) Net Income: -6213000 USD Concept: fundies:NetIncome Period: 2016-01-01 to 2016-12-31 Values: Latest reported Published: 2026-11-02T18:37:57Z Snapshot: df701299cb5fffd82f916455b60e1c4efcc69a41535e456c8ef8cf69576cef32 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1551986/explain?concept=fundies%3ANetIncome&period=2016-12-31&surface=latest&period_type=duration&start=2016-01-01&unit=USD&dimensions= Input fundies:NetIncome: -6213000 USD (2016-01-01 to 2016-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1551986/000114420418014481/innt-20171231.xml#101914 Filing: 000114420418014481 The citation records this snapshot. The page link may show a newer release later.	−USD 8.43 million Exact value Exact value: -8427000 USD 2016-01-01 – 2016-12-31: -8427000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · INNOVATE BIOPHARMACEUTICALS, INC. · 2016-12-31 INNOVATE BIOPHARMACEUTICALS, INC. (edgar:1551986) Operating Cash Flow: -8427000 USD Concept: fundies:OperatingCashFlow Period: 2016-01-01 to 2016-12-31 Values: Latest reported Published: 2026-11-02T18:37:57Z Snapshot: df701299cb5fffd82f916455b60e1c4efcc69a41535e456c8ef8cf69576cef32 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1551986/explain?concept=fundies%3AOperatingCashFlow&period=2016-12-31&surface=latest&period_type=duration&start=2016-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -8427000 USD (2016-01-01 to 2016-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1551986/000114420418014481/innt-20171231.xml#107632 Filing: 000114420418014481 The citation records this snapshot. The page link may show a newer release later.	Unavailable Not reported for this period.	Unavailable Free cash flow cannot be calculated because Capital expenditure is unavailable for this period.
2017 2017-01-01 – 2017-12-31	−USD 11.61 million Exact value Exact value: -11605817 USD 2017-01-01 – 2017-12-31: -11605817 USD Inspect Net Income Open source Share or cite Citation for Net Income · INNOVATE BIOPHARMACEUTICALS, INC. · 2017-12-31 INNOVATE BIOPHARMACEUTICALS, INC. (edgar:1551986) Net Income: -11605817 USD Concept: fundies:NetIncome Period: 2017-01-01 to 2017-12-31 Values: Latest reported Published: 2026-11-02T18:37:57Z Snapshot: df701299cb5fffd82f916455b60e1c4efcc69a41535e456c8ef8cf69576cef32 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1551986/explain?concept=fundies%3ANetIncome&period=2017-12-31&surface=latest&period_type=duration&start=2017-01-01&unit=USD&dimensions= Input fundies:NetIncome: -11605817 USD (2017-01-01 to 2017-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1551986/000155198619000019/innt-20181231.xml#203397 Filing: 000155198619000019 The citation records this snapshot. The page link may show a newer release later.	−USD 5.1 million Exact value Exact value: -5096546 USD 2017-01-01 – 2017-12-31: -5096546 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · INNOVATE BIOPHARMACEUTICALS, INC. · 2017-12-31 INNOVATE BIOPHARMACEUTICALS, INC. (edgar:1551986) Operating Cash Flow: -5096546 USD Concept: fundies:OperatingCashFlow Period: 2017-01-01 to 2017-12-31 Values: Latest reported Published: 2026-11-02T18:37:57Z Snapshot: df701299cb5fffd82f916455b60e1c4efcc69a41535e456c8ef8cf69576cef32 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1551986/explain?concept=fundies%3AOperatingCashFlow&period=2017-12-31&surface=latest&period_type=duration&start=2017-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -5096546 USD (2017-01-01 to 2017-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1551986/000155198619000019/innt-20181231.xml#202976 Filing: 000155198619000019 The citation records this snapshot. The page link may show a newer release later.	USD 38,727 Exact value Exact value: 38727 USD 2017-01-01 – 2017-12-31: 38727 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · INNOVATE BIOPHARMACEUTICALS, INC. · 2017-12-31 INNOVATE BIOPHARMACEUTICALS, INC. (edgar:1551986) Capital Expenditure: 38727 USD Concept: fundies:CapitalExpenditure Period: 2017-01-01 to 2017-12-31 Values: Latest reported Published: 2026-11-02T18:37:57Z Snapshot: df701299cb5fffd82f916455b60e1c4efcc69a41535e456c8ef8cf69576cef32 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1551986/explain?concept=fundies%3ACapitalExpenditure&period=2017-12-31&surface=latest&period_type=duration&start=2017-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 38727 USD (2017-01-01 to 2017-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1551986/000155198619000019/innt-20181231.xml#212754 Filing: 000155198619000019 The citation records this snapshot. The page link may show a newer release later.	−USD 5.14 million Calculation and evidence -5096546 − 38727 USD Exact free cash flow: -5135273 USD 2017-01-01 – 2017-12-31: -5096546 USD · Inspect Operating Cash Flow · Source 2017-01-01 – 2017-12-31: 38727 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · INNOVATE BIOPHARMACEUTICALS, INC. · 2017-12-31 INNOVATE BIOPHARMACEUTICALS, INC. (edgar:1551986) Free cash flow: -5135273 USD Concept: free-cash-flow Period: 2017-01-01 to 2017-12-31 Values: Latest reported Published: 2026-11-02T18:37:57Z Snapshot: df701299cb5fffd82f916455b60e1c4efcc69a41535e456c8ef8cf69576cef32 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1551986?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -5096546 USD (2017-01-01 to 2017-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1551986/000155198619000019/innt-20181231.xml#202976 Filing: 000155198619000019 Input fundies:CapitalExpenditure: 38727 USD (2017-01-01 to 2017-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1551986/000155198619000019/innt-20181231.xml#212754 Filing: 000155198619000019 The citation records this snapshot. The page link may show a newer release later.
2018 2018-01-01 – 2018-12-31	−USD 24.16 million Exact value Exact value: -24162279 USD 2018-01-01 – 2018-12-31: -24162279 USD Inspect Net Income Open source Share or cite Citation for Net Income · INNOVATE BIOPHARMACEUTICALS, INC. · 2018-12-31 INNOVATE BIOPHARMACEUTICALS, INC. (edgar:1551986) Net Income: -24162279 USD Concept: fundies:NetIncome Period: 2018-01-01 to 2018-12-31 Values: Latest reported Published: 2026-11-02T18:37:57Z Snapshot: df701299cb5fffd82f916455b60e1c4efcc69a41535e456c8ef8cf69576cef32 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1551986/explain?concept=fundies%3ANetIncome&period=2018-12-31&surface=latest&period_type=duration&start=2018-01-01&unit=USD&dimensions= Input fundies:NetIncome: -24162279 USD (2018-01-01 to 2018-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1551986/000155198620000050/innt-20191231.xml#297478 Filing: 000155198620000050 The citation records this snapshot. The page link may show a newer release later.	−USD 15.17 million Exact value Exact value: -15169330 USD 2018-01-01 – 2018-12-31: -15169330 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · INNOVATE BIOPHARMACEUTICALS, INC. · 2018-12-31 INNOVATE BIOPHARMACEUTICALS, INC. (edgar:1551986) Operating Cash Flow: -15169330 USD Concept: fundies:OperatingCashFlow Period: 2018-01-01 to 2018-12-31 Values: Latest reported Published: 2026-11-02T18:37:57Z Snapshot: df701299cb5fffd82f916455b60e1c4efcc69a41535e456c8ef8cf69576cef32 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1551986/explain?concept=fundies%3AOperatingCashFlow&period=2018-12-31&surface=latest&period_type=duration&start=2018-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -15169330 USD (2018-01-01 to 2018-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1551986/000155198620000050/innt-20191231.xml#297056 Filing: 000155198620000050 The citation records this snapshot. The page link may show a newer release later.	USD 13,943 Exact value Exact value: 13943 USD 2018-01-01 – 2018-12-31: 13943 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · INNOVATE BIOPHARMACEUTICALS, INC. · 2018-12-31 INNOVATE BIOPHARMACEUTICALS, INC. (edgar:1551986) Capital Expenditure: 13943 USD Concept: fundies:CapitalExpenditure Period: 2018-01-01 to 2018-12-31 Values: Latest reported Published: 2026-11-02T18:37:57Z Snapshot: df701299cb5fffd82f916455b60e1c4efcc69a41535e456c8ef8cf69576cef32 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1551986/explain?concept=fundies%3ACapitalExpenditure&period=2018-12-31&surface=latest&period_type=duration&start=2018-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 13943 USD (2018-01-01 to 2018-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1551986/000155198620000050/innt-20191231.xml#303710 Filing: 000155198620000050 The citation records this snapshot. The page link may show a newer release later.	−USD 15.18 million Calculation and evidence -15169330 − 13943 USD Exact free cash flow: -15183273 USD 2018-01-01 – 2018-12-31: -15169330 USD · Inspect Operating Cash Flow · Source 2018-01-01 – 2018-12-31: 13943 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · INNOVATE BIOPHARMACEUTICALS, INC. · 2018-12-31 INNOVATE BIOPHARMACEUTICALS, INC. (edgar:1551986) Free cash flow: -15183273 USD Concept: free-cash-flow Period: 2018-01-01 to 2018-12-31 Values: Latest reported Published: 2026-11-02T18:37:57Z Snapshot: df701299cb5fffd82f916455b60e1c4efcc69a41535e456c8ef8cf69576cef32 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1551986?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -15169330 USD (2018-01-01 to 2018-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1551986/000155198620000050/innt-20191231.xml#297056 Filing: 000155198620000050 Input fundies:CapitalExpenditure: 13943 USD (2018-01-01 to 2018-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1551986/000155198620000050/innt-20191231.xml#303710 Filing: 000155198620000050 The citation records this snapshot. The page link may show a newer release later.
2019 2019-01-01 – 2019-12-31	−USD 27.05 million Exact value Exact value: -27048808 USD 2019-01-01 – 2019-12-31: -27048808 USD Inspect Net Income Open source Share or cite Citation for Net Income · INNOVATE BIOPHARMACEUTICALS, INC. · 2019-12-31 INNOVATE BIOPHARMACEUTICALS, INC. (edgar:1551986) Net Income: -27048808 USD Concept: fundies:NetIncome Period: 2019-01-01 to 2019-12-31 Values: Latest reported Published: 2026-11-02T18:37:57Z Snapshot: df701299cb5fffd82f916455b60e1c4efcc69a41535e456c8ef8cf69576cef32 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1551986/explain?concept=fundies%3ANetIncome&period=2019-12-31&surface=latest&period_type=duration&start=2019-01-01&unit=USD&dimensions= Input fundies:NetIncome: -27048808 USD (2019-01-01 to 2019-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1551986/000155198621000033/nmtr-20201231.htm#1525706 Filing: 000155198621000033 The citation records this snapshot. The page link may show a newer release later.	−USD 17.97 million Exact value Exact value: -17967992 USD 2019-01-01 – 2019-12-31: -17967992 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · INNOVATE BIOPHARMACEUTICALS, INC. · 2019-12-31 INNOVATE BIOPHARMACEUTICALS, INC. (edgar:1551986) Operating Cash Flow: -17967992 USD Concept: fundies:OperatingCashFlow Period: 2019-01-01 to 2019-12-31 Values: Latest reported Published: 2026-11-02T18:37:57Z Snapshot: df701299cb5fffd82f916455b60e1c4efcc69a41535e456c8ef8cf69576cef32 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1551986/explain?concept=fundies%3AOperatingCashFlow&period=2019-12-31&surface=latest&period_type=duration&start=2019-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -17967992 USD (2019-01-01 to 2019-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1551986/000155198621000033/nmtr-20201231.htm#1567236 Filing: 000155198621000033 The citation records this snapshot. The page link may show a newer release later.	USD 11,934 Exact value Exact value: 11934 USD 2019-01-01 – 2019-12-31: 11934 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · INNOVATE BIOPHARMACEUTICALS, INC. · 2019-12-31 INNOVATE BIOPHARMACEUTICALS, INC. (edgar:1551986) Capital Expenditure: 11934 USD Concept: fundies:CapitalExpenditure Period: 2019-01-01 to 2019-12-31 Values: Latest reported Published: 2026-11-02T18:37:57Z Snapshot: df701299cb5fffd82f916455b60e1c4efcc69a41535e456c8ef8cf69576cef32 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1551986/explain?concept=fundies%3ACapitalExpenditure&period=2019-12-31&surface=latest&period_type=duration&start=2019-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 11934 USD (2019-01-01 to 2019-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1551986/000155198621000033/nmtr-20201231.htm#1570487 Filing: 000155198621000033 The citation records this snapshot. The page link may show a newer release later.	−USD 17.98 million Calculation and evidence -17967992 − 11934 USD Exact free cash flow: -17979926 USD 2019-01-01 – 2019-12-31: -17967992 USD · Inspect Operating Cash Flow · Source 2019-01-01 – 2019-12-31: 11934 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · INNOVATE BIOPHARMACEUTICALS, INC. · 2019-12-31 INNOVATE BIOPHARMACEUTICALS, INC. (edgar:1551986) Free cash flow: -17979926 USD Concept: free-cash-flow Period: 2019-01-01 to 2019-12-31 Values: Latest reported Published: 2026-11-02T18:37:57Z Snapshot: df701299cb5fffd82f916455b60e1c4efcc69a41535e456c8ef8cf69576cef32 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1551986?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -17967992 USD (2019-01-01 to 2019-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1551986/000155198621000033/nmtr-20201231.htm#1567236 Filing: 000155198621000033 Input fundies:CapitalExpenditure: 11934 USD (2019-01-01 to 2019-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1551986/000155198621000033/nmtr-20201231.htm#1570487 Filing: 000155198621000033 The citation records this snapshot. The page link may show a newer release later.
2020 2020-01-01 – 2020-12-31	−USD 61.5 million Exact value Exact value: -61496489 USD 2020-01-01 – 2020-12-31: -61496489 USD Inspect Net Income Open source Share or cite Citation for Net Income · INNOVATE BIOPHARMACEUTICALS, INC. · 2020-12-31 INNOVATE BIOPHARMACEUTICALS, INC. (edgar:1551986) Net Income: -61496489 USD Concept: fundies:NetIncome Period: 2020-01-01 to 2020-12-31 Values: Latest reported Published: 2026-11-02T18:37:57Z Snapshot: df701299cb5fffd82f916455b60e1c4efcc69a41535e456c8ef8cf69576cef32 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1551986/explain?concept=fundies%3ANetIncome&period=2020-12-31&surface=latest&period_type=duration&start=2020-01-01&unit=USD&dimensions= Input fundies:NetIncome: -61496489 USD (2020-01-01 to 2020-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1551986/000155198622000030/nmtr-20211231.htm#1384274 Filing: 000155198622000030 The citation records this snapshot. The page link may show a newer release later.	−USD 19.41 million Exact value Exact value: -19409786 USD 2020-01-01 – 2020-12-31: -19409786 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · INNOVATE BIOPHARMACEUTICALS, INC. · 2020-12-31 INNOVATE BIOPHARMACEUTICALS, INC. (edgar:1551986) Operating Cash Flow: -19409786 USD Concept: fundies:OperatingCashFlow Period: 2020-01-01 to 2020-12-31 Values: Latest reported Published: 2026-11-02T18:37:57Z Snapshot: df701299cb5fffd82f916455b60e1c4efcc69a41535e456c8ef8cf69576cef32 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1551986/explain?concept=fundies%3AOperatingCashFlow&period=2020-12-31&surface=latest&period_type=duration&start=2020-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -19409786 USD (2020-01-01 to 2020-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1551986/000155198622000030/nmtr-20211231.htm#1419880 Filing: 000155198622000030 The citation records this snapshot. The page link may show a newer release later.	USD 2,543 Exact value Exact value: 2543 USD 2020-01-01 – 2020-12-31: 2543 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · INNOVATE BIOPHARMACEUTICALS, INC. · 2020-12-31 INNOVATE BIOPHARMACEUTICALS, INC. (edgar:1551986) Capital Expenditure: 2543 USD Concept: fundies:CapitalExpenditure Period: 2020-01-01 to 2020-12-31 Values: Latest reported Published: 2026-11-02T18:37:57Z Snapshot: df701299cb5fffd82f916455b60e1c4efcc69a41535e456c8ef8cf69576cef32 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1551986/explain?concept=fundies%3ACapitalExpenditure&period=2020-12-31&surface=latest&period_type=duration&start=2020-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 2543 USD (2020-01-01 to 2020-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1551986/000155198622000030/nmtr-20211231.htm#1423146 Filing: 000155198622000030 The citation records this snapshot. The page link may show a newer release later.	−USD 19.41 million Calculation and evidence -19409786 − 2543 USD Exact free cash flow: -19412329 USD 2020-01-01 – 2020-12-31: -19409786 USD · Inspect Operating Cash Flow · Source 2020-01-01 – 2020-12-31: 2543 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · INNOVATE BIOPHARMACEUTICALS, INC. · 2020-12-31 INNOVATE BIOPHARMACEUTICALS, INC. (edgar:1551986) Free cash flow: -19412329 USD Concept: free-cash-flow Period: 2020-01-01 to 2020-12-31 Values: Latest reported Published: 2026-11-02T18:37:57Z Snapshot: df701299cb5fffd82f916455b60e1c4efcc69a41535e456c8ef8cf69576cef32 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1551986?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -19409786 USD (2020-01-01 to 2020-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1551986/000155198622000030/nmtr-20211231.htm#1419880 Filing: 000155198622000030 Input fundies:CapitalExpenditure: 2543 USD (2020-01-01 to 2020-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1551986/000155198622000030/nmtr-20211231.htm#1423146 Filing: 000155198622000030 The citation records this snapshot. The page link may show a newer release later.
2021 2021-01-01 – 2021-12-31	−USD 36.78 million Exact value Exact value: -36779400 USD 2021-01-01 – 2021-12-31: -36779400 USD Inspect Net Income Open source Share or cite Citation for Net Income · INNOVATE BIOPHARMACEUTICALS, INC. · 2021-12-31 INNOVATE BIOPHARMACEUTICALS, INC. (edgar:1551986) Net Income: -36779400 USD Concept: fundies:NetIncome Period: 2021-01-01 to 2021-12-31 Values: Latest reported Published: 2026-11-02T18:37:57Z Snapshot: df701299cb5fffd82f916455b60e1c4efcc69a41535e456c8ef8cf69576cef32 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1551986/explain?concept=fundies%3ANetIncome&period=2021-12-31&surface=latest&period_type=duration&start=2021-01-01&unit=USD&dimensions= Input fundies:NetIncome: -36779400 USD (2021-01-01 to 2021-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1551986/000155198623000021/nmtr-20221231.htm#1038643 Filing: 000155198623000021 The citation records this snapshot. The page link may show a newer release later.	−USD 29.48 million Exact value Exact value: -29478275 USD 2021-01-01 – 2021-12-31: -29478275 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · INNOVATE BIOPHARMACEUTICALS, INC. · 2021-12-31 INNOVATE BIOPHARMACEUTICALS, INC. (edgar:1551986) Operating Cash Flow: -29478275 USD Concept: fundies:OperatingCashFlow Period: 2021-01-01 to 2021-12-31 Values: Latest reported Published: 2026-11-02T18:37:57Z Snapshot: df701299cb5fffd82f916455b60e1c4efcc69a41535e456c8ef8cf69576cef32 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1551986/explain?concept=fundies%3AOperatingCashFlow&period=2021-12-31&surface=latest&period_type=duration&start=2021-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -29478275 USD (2021-01-01 to 2021-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1551986/000155198623000021/nmtr-20221231.htm#1060154 Filing: 000155198623000021 The citation records this snapshot. The page link may show a newer release later.	USD 12,476 Exact value Exact value: 12476 USD 2021-01-01 – 2021-12-31: 12476 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · INNOVATE BIOPHARMACEUTICALS, INC. · 2021-12-31 INNOVATE BIOPHARMACEUTICALS, INC. (edgar:1551986) Capital Expenditure: 12476 USD Concept: fundies:CapitalExpenditure Period: 2021-01-01 to 2021-12-31 Values: Latest reported Published: 2026-11-02T18:37:57Z Snapshot: df701299cb5fffd82f916455b60e1c4efcc69a41535e456c8ef8cf69576cef32 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1551986/explain?concept=fundies%3ACapitalExpenditure&period=2021-12-31&surface=latest&period_type=duration&start=2021-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 12476 USD (2021-01-01 to 2021-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1551986/000155198623000021/nmtr-20221231.htm#1062596 Filing: 000155198623000021 The citation records this snapshot. The page link may show a newer release later.	−USD 29.49 million Calculation and evidence -29478275 − 12476 USD Exact free cash flow: -29490751 USD 2021-01-01 – 2021-12-31: -29478275 USD · Inspect Operating Cash Flow · Source 2021-01-01 – 2021-12-31: 12476 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · INNOVATE BIOPHARMACEUTICALS, INC. · 2021-12-31 INNOVATE BIOPHARMACEUTICALS, INC. (edgar:1551986) Free cash flow: -29490751 USD Concept: free-cash-flow Period: 2021-01-01 to 2021-12-31 Values: Latest reported Published: 2026-11-02T18:37:57Z Snapshot: df701299cb5fffd82f916455b60e1c4efcc69a41535e456c8ef8cf69576cef32 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1551986?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -29478275 USD (2021-01-01 to 2021-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1551986/000155198623000021/nmtr-20221231.htm#1060154 Filing: 000155198623000021 Input fundies:CapitalExpenditure: 12476 USD (2021-01-01 to 2021-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1551986/000155198623000021/nmtr-20221231.htm#1062596 Filing: 000155198623000021 The citation records this snapshot. The page link may show a newer release later.
2022 2022-01-01 – 2022-12-31	−USD 43.77 million Exact value Exact value: -43766415 USD 2022-01-01 – 2022-12-31: -43766415 USD Inspect Net Income Open source Share or cite Citation for Net Income · INNOVATE BIOPHARMACEUTICALS, INC. · 2022-12-31 INNOVATE BIOPHARMACEUTICALS, INC. (edgar:1551986) Net Income: -43766415 USD Concept: fundies:NetIncome Period: 2022-01-01 to 2022-12-31 Values: Latest reported Published: 2026-11-02T18:37:57Z Snapshot: df701299cb5fffd82f916455b60e1c4efcc69a41535e456c8ef8cf69576cef32 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1551986/explain?concept=fundies%3ANetIncome&period=2022-12-31&surface=latest&period_type=duration&start=2022-01-01&unit=USD&dimensions= Input fundies:NetIncome: -43766415 USD (2022-01-01 to 2022-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1551986/000155198623000021/nmtr-20221231.htm#1037802 Filing: 000155198623000021 The citation records this snapshot. The page link may show a newer release later.	−USD 37.24 million Exact value Exact value: -37243217 USD 2022-01-01 – 2022-12-31: -37243217 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · INNOVATE BIOPHARMACEUTICALS, INC. · 2022-12-31 INNOVATE BIOPHARMACEUTICALS, INC. (edgar:1551986) Operating Cash Flow: -37243217 USD Concept: fundies:OperatingCashFlow Period: 2022-01-01 to 2022-12-31 Values: Latest reported Published: 2026-11-02T18:37:57Z Snapshot: df701299cb5fffd82f916455b60e1c4efcc69a41535e456c8ef8cf69576cef32 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1551986/explain?concept=fundies%3AOperatingCashFlow&period=2022-12-31&surface=latest&period_type=duration&start=2022-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -37243217 USD (2022-01-01 to 2022-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1551986/000155198623000021/nmtr-20221231.htm#1059432 Filing: 000155198623000021 The citation records this snapshot. The page link may show a newer release later.	USD 2,842 Exact value Exact value: 2842 USD 2022-01-01 – 2022-12-31: 2842 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · INNOVATE BIOPHARMACEUTICALS, INC. · 2022-12-31 INNOVATE BIOPHARMACEUTICALS, INC. (edgar:1551986) Capital Expenditure: 2842 USD Concept: fundies:CapitalExpenditure Period: 2022-01-01 to 2022-12-31 Values: Latest reported Published: 2026-11-02T18:37:57Z Snapshot: df701299cb5fffd82f916455b60e1c4efcc69a41535e456c8ef8cf69576cef32 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1551986/explain?concept=fundies%3ACapitalExpenditure&period=2022-12-31&surface=latest&period_type=duration&start=2022-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 2842 USD (2022-01-01 to 2022-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1551986/000155198623000021/nmtr-20221231.htm#1061946 Filing: 000155198623000021 The citation records this snapshot. The page link may show a newer release later.	−USD 37.25 million Calculation and evidence -37243217 − 2842 USD Exact free cash flow: -37246059 USD 2022-01-01 – 2022-12-31: -37243217 USD · Inspect Operating Cash Flow · Source 2022-01-01 – 2022-12-31: 2842 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · INNOVATE BIOPHARMACEUTICALS, INC. · 2022-12-31 INNOVATE BIOPHARMACEUTICALS, INC. (edgar:1551986) Free cash flow: -37246059 USD Concept: free-cash-flow Period: 2022-01-01 to 2022-12-31 Values: Latest reported Published: 2026-11-02T18:37:57Z Snapshot: df701299cb5fffd82f916455b60e1c4efcc69a41535e456c8ef8cf69576cef32 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1551986?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -37243217 USD (2022-01-01 to 2022-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1551986/000155198623000021/nmtr-20221231.htm#1059432 Filing: 000155198623000021 Input fundies:CapitalExpenditure: 2842 USD (2022-01-01 to 2022-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1551986/000155198623000021/nmtr-20221231.htm#1061946 Filing: 000155198623000021 The citation records this snapshot. The page link may show a newer release later.

Capital expenditure uses the canonical mapped positive-spending convention. A missing, ambiguous, incompatible, or negative-sign input is left blank. Values use the latest reported version.

Dataset coverage and company identifiers

Coverage reflects filings processed into this Fundies dataset; it does not imply every source filing is loaded.

49 filings · 1,660 latest values · 1,660 originally reported values

Dataset published 2026-11-02. Source filing dates and reporting periods are shown separately.

Identifiers: 0001551986, 1551986, INNT, MSDI, NMTR, edgar:1551986

Also known as 9 METERS BIOPHARMA, INC., 9 METERS BIOPHARMA, INC. , INNOVATE BIOPHARMACEUTICALS, INC., Monster Digital, Inc., Tandon Digital, Inc.

INNOVATE BIOPHARMACEUTICALS, INC.

Reported share-count change

Trailing twelve months

Net income

Operating cash flow

Capital expenditure

Free cash flow

Company performance

What changed year over year

Net income

Operating cash flow

Capital expenditure

Where revenue goes

Growth

Profit and cash

Balance sheet

Cash generation